nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

28.03.2022 | Original Article

Diagnostic performance of total-body ¹⁸F-FDG PET/CT with fast 2-min acquisition for liver tumours: comparison with conventional PET/CT

verfasst von: Yan Hu, Guobing Liu, Haojun Yu, Jianying Gu, Hongcheng Shi

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 10/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To comparatively evaluate the diagnostic performances of total-body ¹⁸F-fluorodeoxyglucose positron-emission tomography/computed tomography (¹⁸F-FDG PET/CT) with fast 2-min acquisition and conventional PET/CT in liver cancer patients.

Methods

This study included 156 patients with liver tumours. Seventy-eight patients underwent total-body PET/CT. PET raw data were reconstructed using acquisition durations of 2 min (G2) and 15 min (G15). Another 78 patients with liver lesions (control patients) underwent conventional uMI780 PET/CT (G780). All patients were evaluated based on TNM staging. The maximum tumour standardized uptake value (tumour SUVmax), mean normal liver SUV (SUVmean), and tumour SUVmax-to-liver SUVmean ratio (TLR) were determined for all patients. G15 data were used as the reference in the lesion detectability analysis. The diagnostic performances of PET/CT in terms of visual parameters and of PET in terms of semi-quantitative parameters such as SUVmax and TLR were evaluated. Receiver operating characteristics (ROC) curve analysis of SUVmax and TLR at G2 was performed. Pathologic findings of surgical specimens served as the gold standard for all patients.

Results

The lesions found in G15 were also noted in G2; three lymph nodes were missed in G2. However, no significant difference was found in the TNM stage among G2, G15, and G780. For benign and malignant lesions, the liver SUVmean in G2 and G15 was higher than that in G780 (all P < 0.05). The tumour SUVmax and TLR in G2 were equivalent to those in G15 and G780 regardless of whether the lesions were benign or malignant. ROC curve analysis (SUVmax cutoff: 4.34, TLR cutoff: 1.34) demonstrated that G2 also had good sensitivity in detecting liver cancer.

Conclusion

The diagnostic performance of total-body PET/CT in G2 was comparable to that in G15 among liver cancer patients. Further, the diagnostic efficiency of total-body PET/CT imaging with fast 2-min acquisition and conventional PET/CT was similar.

Nur mit Berechtigung zugänglich

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492.CrossRefPubMed

Anwanwan D, Singh SK, Singh S, Saikam V, Singh R. Challenges in liver cancer and possible treatment approaches. Biochimica Biophysica Acta Rev Cancer. 2020;1873(1):188314. https://doi.org/10.1016/j.bbcan.2019.188314.CrossRef

Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology. 2010;51(5):1820–32. https://doi.org/10.1002/hep.23594.CrossRefPubMed

Zhou M, Wang H, Zeng X, Yin P, Zhu J, Chen W, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet. 2019;394(10204):1145–58. https://doi.org/10.1016/S0140-6736(19)30427-1.CrossRef

Benson AB, D’Angelica MI, Abbott DE, Abrams TA, Alberts SR, Anaya DA, et al. Guidelines insights: hepatobiliary cancers, version 2.2019. J Natl Compr Canc Netw. 2019;17(4):302–10. https://doi.org/10.6004/jnccn.2019.0019.CrossRefPubMed

Ayuso C, Rimola J, Vilana R, Burrel M, Darnell A, Garcia-Criado A, et al. Diagnosis and staging of hepatocellular carcinoma (HCC): current guidelines. Eur J Radiol. 2018;101:72–81. https://doi.org/10.1016/j.ejrad.2018.01.025.CrossRefPubMed

Na SJ, Oh JK, Hyun SH, Lee JW, Hong IK, Song B, et al. 18F-FDG PET/CT can predict survival of advanced hepatocellular carcinoma patients: a multicenter retrospective cohort study. J Nucl Med. 2017;58(5):730–6. https://doi.org/10.2967/jnumed.116.182022.CrossRefPubMed

Lee SM, Kim HS, Lee S, Lee JW. Emerging role of (18)F-fluorodeoxyglucose positron emission tomography for guiding management of hepatocellular carcinoma. World J Gastroenterol. 2019;25(11):1289–306. https://doi.org/10.3748/wjg.v25.i11.1289.CrossRefPubMedPubMedCentral

Lu R, She B, Gao W, Ji Y, Xu D, Wang Q, et al. Positron-emission tomography for hepatocellular carcinoma: current status and future prospects. World J Gastroentero. 2019;25(32):4682–95. https://doi.org/10.3748/wjg.v25.i32.4682.CrossRef

10.

Schiller F, Frings L, Thurow J, Meyer PT, Mix M. Limits for reduction of acquisition time and administered activity in (18)F-FDG PET studies of Alzheimer dementia and frontotemporal dementia. J Nucl Med. 2019;60(12):1764–70. https://doi.org/10.2967/jnumed.119.227132.CrossRefPubMed

11.

Boellaard R, Delgado-Bolton R, Oyen WJG, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol I. 2015;42(2):328–54. https://doi.org/10.1007/s00259-014-2961-x.CrossRef

12.

Spencer BA, Berg E, Schmall JP, Omidvari N, Leung EK, Abdelhafez YG, et al. Performance evaluation of the uEXPLORER total-body PET/CT scanner based on NEMA NU 2–2018 with additional tests to characterize PET scanners with a long axial field of view. J Nucl Med. 2021;62(6):861–70. https://doi.org/10.2967/jnumed.120.250597.CrossRefPubMedPubMedCentral

13.

Liu G, Hu P, Yu H, Tan H, Zhang Y, Yin H, et al. Ultra-low-activity total-body dynamic PET imaging allows equal performance to full-activity PET imaging for investigating kinetic metrics of 18F-FDG in healthy volunteers. Eur J Nucl Med Mol I. 2021. https://doi.org/10.1007/s00259-020-05173-3.CrossRef

14.

Tan H, Sui X, Yin H, Yu H, Gu Y, Chen S, et al. Total-body PET/CT using half-dose FDG and compared with conventional PET/CT using full-dose FDG in lung cancer. Eur J Nucl Med Mol I. 2021;48(6):1966–75. https://doi.org/10.1007/s00259-020-05091-4.CrossRef

15.

Zhang Y, Hu P, Wu R, Gu Y, Chen S, Yu H, et al. The image quality, lesion detectability, and acquisition time of 18F-FDG total-body PET/CT in oncological patients. Eur J Nucl Med Mol I. 2020;47(11):2507–15. https://doi.org/10.1007/s00259-020-04823-w.CrossRef

16.

Hu P, Zhang Y, Yu H, Chen S, Tan H, Qi C, et al. Total-body (18)F-FDG PET/CT scan in oncology patients: how fast could it be? Eur J Nucl Med Mol I. 2021;48(8):2384–94. https://doi.org/10.1007/s00259-021-05357-5.CrossRef

17.

Lamarca A, Santos Laso A, Utpatel K, la Casta A, Stock S, Forner A, et al. Liver metastases of intrahepatic cholangiocarcinoma: implications for an updated staging system. Hepatology (Baltimore, Md). 2021;73(6):2311–25. https://doi.org/10.1002/hep.31598.CrossRef

18.

Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017;67(2):93–9. https://doi.org/10.3322/caac.21388.CrossRefPubMed

19.

Liu C, Pierce Ii LA, Alessio AM, Kinahan PE. The impact of respiratory motion on tumor quantification and delineation in static PET/CT imaging. Phys Med Biol. 2009;54(24):7345–62. https://doi.org/10.1088/0031-9155/54/24/007.CrossRefPubMedPubMedCentral

20.

Nehmeh SA, Erdi YE. Respiratory motion in positron emission tomography/computed tomography: a review. Semin Nucl Med. 2008;38(3):167–76. https://doi.org/10.1053/j.semnuclmed.2008.01.002.CrossRefPubMed

21.

Zhang X, Zhou J, Cherry SR, Badawi RD, Qi J. Quantitative image reconstruction for total-body PET imaging using the 2-meter long EXPLORER scanner. Phys Med Biol. 2017;62(6):2465–85. https://doi.org/10.1088/1361-6560/aa5e46.CrossRefPubMedPubMedCentral

22.

Zhang X, Cherry SR, Xie Z, Shi H, Badawi RD, Qi J. Subsecond total-body imaging using ultrasensitive positron emission tomography. Proc Natl Acad Sci PNAS. 2020;117(5):2265–7. https://doi.org/10.1073/pnas.1917379117.CrossRefPubMed

23.

Badawi RD, Shi H, Hu P, Chen S, Xu T, Price PM, et al. First human imaging studies with the EXPLORER total-body PET scanner. J Nucl Med. 2019;60(3):299–303. https://doi.org/10.2967/jnumed.119.226498.CrossRefPubMedPubMedCentral

24.

Pantel AR, Viswanath V, Daube-Witherspoon ME, Dubroff JG, Muehllehner G, Parma MJ, et al. PennPET explorer: human imaging on a whole-body imager. J Nucl Med. 2020;61(1):144–51. https://doi.org/10.2967/jnumed.119.231845.CrossRefPubMedPubMedCentral

25.

Xiao J, Yu H, Sui X, Hu Y, Cao Y, Liu G, et al. Can the BMI-based dose regimen be used to reduce injection activity and to obtain a constant image quality in oncological patients by (18)F-FDG total-body PET/CT imaging? Eur J Nucl Med Mol Imaging. 2021;49(1):269–78. https://doi.org/10.1007/s00259-021-05462-5.

26.

Tan H, Sui X, Yin H, Yu H, Gu Y, Chen S, et al. Total-body PET/CT using half-dose FDG and compared with conventional PET/CT using full-dose FDG in lung cancer. Eur J Nucl Med Mol. 2020 Nov;I(2020):27. https://doi.org/10.1007/s00259-020-05091-4.CrossRef

27.

Mawlawi O, Erasmus JJ, Pan T, Cody DD, Campbell R, Lonn AH, et al. Truncation artifact on PET/CT: impact on measurements of activity concentration and assessment of a correction algorithm. AJR Am J Roentgenol. 2006;186(5):1458–67. https://doi.org/10.2214/AJR.05.0255.CrossRefPubMed

Titel: Diagnostic performance of total-body 18F-FDG PET/CT with fast 2-min acquisition for liver tumours: comparison with conventional PET/CT
verfasst von: Yan Hu
Guobing Liu
Haojun Yu
Jianying Gu
Hongcheng Shi
Publikationsdatum: 28.03.2022
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 10/2022
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-022-05772-2

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2022

Quantitative assessment of myelin density using [11C]MeDAS PET in patients with multiple sclerosis: a first-in-human study

Feasibility of [68Ga]Ga-FAPI-46 PET/CT for detection of nodal and hematogenous spread in high-grade urothelial carcinoma

225Ac-DOTATATE therapy in a case of metastatic pheochromocytoma

Lymphopenia in patients affected by SARS-CoV-2 infection is caused by margination of lymphocytes in large bowel: an [18F]FDG PET/CT study

FDG-PET/CT in indeterminate thyroid nodules: cost-utility analysis alongside a randomised controlled trial

Efficacy and safety of 177Lu‑DOTATATE in patients with advanced pancreatic neuroendocrine tumours: data from the NETTER-R international, retrospective study